Analyst Ratings For NASDAQ:CLSD – Clearside Biomedical (NASDAQ:CLSD)
Today, Wedbush reiterated its Outperform rating on NASDAQ:CLSD – Clearside Biomedical (NASDAQ:CLSD) with a price target of $29.00.
Some recent analyst ratings include
- 5/11/2018-Wedbush Reiterated Rating of Outperform.
- 3/6/2018-JPMorgan Chase Reiterated Rating of Overweight ➝ Overweight.
- 3/5/2018-JMP Securities Reiterated Rating of Outperform.
- 10/25/2017-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:CLSD – Clearside Biomedical (NASDAQ:CLSD)
NASDAQ:CLSD – Clearside Biomedical (NASDAQ:CLSD) has insider ownership of 20.90% and institutional ownership of 37.96%.
- On 3/23/2018 Charles A Deignan, CFO, bought 500 with an average share price of $11.79 per share and the total transaction amounting to $5,895.00.
- On 3/22/2018 Gerald D Cagle, Director, bought 7,500 with an average share price of $11.89 per share and the total transaction amounting to $89,175.00.
- On 12/7/2017 Clay Thorp, Director, sold 5,000 with an average share price of $6.13 per share and the total transaction amounting to $30,650.00.
- On 12/5/2017 Clay Thorp, Director, sold 15,000 with an average share price of $6.37 per share and the total transaction amounting to $95,550.00.
- On 11/16/2017 Clay Thorp, Director, sold 35,000 with an average share price of $7.00 per share and the total transaction amounting to $245,000.00.
- On 11/14/2017 Clay Thorp, Director, sold 15,000 with an average share price of $7.02 per share and the total transaction amounting to $105,300.00.
- On 10/19/2017 Daniel H White, Insider, sold 8,000 with an average share price of $7.82 per share and the total transaction amounting to $62,560.00.
Recent Trading Activity for NASDAQ:CLSD – Clearside Biomedical (NASDAQ:CLSD)
Shares of NASDAQ:CLSD – Clearside Biomedical closed the previous trading session at with 11.739999771118164 shares trading hands.